

GLOBAL LIFE SCIENCES FUND

Sector experts seeking growth and innovation in health care

The fund seeks to harness the rapid innovation in health care to generate returns by investing in companies addressing unmet medical needs or those who seek to make the health care system more efficient.

Why Janus Henderson



Health care expertise

Our domain experts have more than a century of combined experience investing in the complex and dynamic health care sector. Our team of specialists, which include multiple Ph.D.s, seek to understand both the science and the business of prospective investments.



Balanced approach

We diversify the fund across market capitalisations, geographies and the primary sub-sectors of health care, including investments in biotechnology, pharmaceuticals, health care services and medical devices.



Integrated risk management process

Security-level “Value at Risk” framework focuses attention on downside risks by limiting the position size of higher-risk stocks.

DRUG LIFE CYCLE – THE SCIENCE AND THE BUSINESS

The team has over 100+ years of combined experience evaluating the **science** and the **business** of bringing drugs to market.



Note: There is no assurance the stated objectives will be met.

WHY HEALTH CARE?


A powerful combination of factors are driving long-term sustainable growth

> ACCELERATING INNOVATION OF DRUG THERAPIES

INCREASE IN FDA APPROVED DRUGS¹



> GLOBALISATION



Health care spending per capita will grow at an average annual rate of

2.7%

across OECD member countries³

> AGING POPULATION



On average, those over the age of 65 spend 3x more on health care. As of 2019, one in 11 people in the world were over the age of 65 (11%). By 2050, one in six people in the world will be over age 65 (16%), leading to increased health care spending.⁴

> DEFENSIVE GROWTH CHARACTERISTICS

51%


Health care has held up better in down equity markets, with the MSCI World Health Care IndexSM averaging 51% downside capture of MSCI World IndexSM returns.⁵

Sources: ¹FDA, as of January 2021. ²Census, World Population, as of July 2020. ³OECD, as of November 2019. ⁴United Nations, un.org as of December 2019.

⁵Janus Henderson Investors, FactSet, as of December 31, 2020. 51% represents the MSCI World Health Care Index average downside capture of the MSCI World Index returns over four distinct time periods 4/2000-9/2002, 11/2007-2/2009, 5/2011-9/2011 and 2/2020-3/2020 with downside captures averaging 31%, 64%, 49% and 59%, respectively.

The case for active management: “90/90 rule”

The two primary concerns when investing in therapeutics are the clinical and commercial risks. At Janus Henderson, we call this the “90/90 rule.”



90% OF DRUGS THAT ENTER HUMAN CLINICAL TRIALS NEVER MAKE IT TO THE MARKET.

90% OF THE TIME CONSENSUS ESTIMATES FOR NEW DRUG LAUNCHES ARE WRONG, IN OUR EXPERIENCE.

Accelerating innovation is addressing unmet medical needs

Opportunities that exist in today's day and age



CANCER

Moving from indiscriminate chemotherapies and radiation to more targeted immuno-oncology treatments that leverage, rather than attack, the body's immune system.



DIABETES

New medical devices harmonise the use of continuous glucose monitoring and glucose pumps to provide revolutionary ways for diabetics to manage their disease.



GENETIC DISEASE

New advances in gene therapy offer the promise of treating 7,000+ genetic diseases, 95% of which currently have no available treatment.⁶



ROBOTIC SURGERY

Robotic surgery can improve accuracy beyond the human hand and offers patients the promise of better outcomes with less pain and faster recoveries.



COVID-19

Prior to 2020, the average vaccine took 10 years to bring to market. In 2020, with new technologies, two vaccines reached the market in only **10 months**. These vaccines were **95% effective**.

Portfolio management



Andy Acker, CFA

- Portfolio manager since 2007
- Industry since 1996

Fund facts

Structure	Irish Investment Company (IIC)
Inception date	31 March 2000
AUM	USD 3.9b (as at 31 December 2020)
Benchmark	MSCI World Health Care
Performance target	To outperform the MSCI World Health Care Index by at least 2% per annum, before the deduction of charges, over any 5 year period.
Sector	Morningstar Equity Healthcare
Expected tracking error range	400 – 800 bps
Holdings range	70 – 100
Expected annual turnover	~ 50%
Position size	25 to 500 basis points. Position sizes may exceed 5% in order to gain active exposure to a large index holding.
Market cap range	Typically, diversified and balanced across large (> \$10B), mid (\$3B – 10B) and small (< \$3B). We generally focus on companies with > \$500M market capitalisations to ensure scalability of the product.
Base currency	USD

Ranges are reflective of the portfolio managers investment process and style at time of publication. They may not be hard limits and are subject to change without notice. For a list of available share classes, please contact your local sales representative.

Role in a diversified portfolio

Portfolio position



Traditional equity
Health care exposure

Portfolio implementation ▪ Complement traditional equity strategies

What this offers investors ▪ Long-term growth of capital
 ▪ Experienced team

For Dutch Investors Only

FOR MORE INFORMATION, PLEASE VISIT JANUSHENDERSON.COM

Janus Henderson

INVESTORS

All content in this document is for information or general use only and is not specific to any individual client requirements.

The investments underlying this financial product (referred to as the Fund) do not take into account the EU criteria for environmentally sustainable economic activities. While the analysis of ESG factors is an integral component across the Investment Manager's investment capabilities, the Investment Manager does not maximise portfolio alignment with sustainability risks as a separate goal in its own right nor does it precisely attribute the impact of ESG factors on returns for the Fund.

Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. Past performance is not indicative of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. This is not a solicitation for the sale of shares and nothing herein is intended to amount to investment advice. This document does not constitute investment advice or an offer to sell, buy or a recommendation, nor should it be taken as a basis to take (or stop taking) any decision, for securities, other than pursuant to an agreement in compliance with applicable laws, rules and regulations. Janus Henderson Group plc and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this document and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. As with all investments, there are inherent risks that each individual should address. The distribution of this document or the information contained in it may be restricted by law and may not be used in any jurisdiction or any circumstances in which its use would be unlawful. This presentation is strictly private and confidential and may not be reproduced or used for any purpose other than evaluation of a potential investment in Janus Capital International Limited's products or the procurement of its services by the recipient of this presentation or provided to any person or entity other than the recipient of this presentation. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Issued in Europe by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Capital International Limited (reg. no. 3594615), Henderson Global Investors Limited (reg. no. 906355), Henderson Investment Funds Limited (reg. no. 2678531), Henderson Equity Partners Limited (reg. no. 2606646), (each registered in England and Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial Conduct Authority) and Henderson Management S.A. (reg. no. B22848 at 2 Rue de Bittbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier). The extract prospectus (edition for Switzerland), the articles of incorporation, the extract annual and semi-annual report, in German, can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd ("FIFS"), Klausstrasse 33, CH-8008 Zurich, Switzerland, tel: +41 44 206 16 40, fax: +41 44 206 16 41, web: <http://www.fifs.ch>. The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l'Île, CH-1204 Geneva. The last share prices can be found on www.fundinfo.com. For Qualified investors, institutional, wholesale client use only. Austrian investors may obtain the current prospectus and simplified prospectus free of charge at Bank Austria Creditanstalt AG, AM Hof 2, 1010 Wien, Austria. This document is not for public distribution in Belgium. German investors may obtain the current prospectus and simplified prospectus free of charge at State Street Bank GmbH, Brienner Str. 59, D-80333, Munich, Germany. The Fund has been registered under the Act of the supervision of investment institutions in the Netherlands. Dutch investors may obtain the current prospectus, simplified prospectus, annual report, semi annual report and Memorandum & Articles of Association from Citi Funds Services (Ireland) Ltd (in their capacity as administrator). Janus Henderson Capital Funds Plc is an Irish collective investment scheme (IIC) registered in the National Securities Market Commission's (CNMV) registry with registration number 265. As of the 6th of July its custodian is JP Morgan Bank (Ireland) Plc and its Investment Advisor is Janus Capital International Limited, authorised and regulated by the Financial Conduct Authority. Investors are warned that they should make their investments based on the IIC's latest documentation. You may consult with and request from the distributor (Allfunds Bank, S.A.) and subdistributors in Spain as well as from the registries of the CNMV a copy of the marketing memorandum, the prospectus and the latest published economic reports. The Custodian in Spain is Santander Securities Services, S.A. This document is intended to be distributed in Italy only to persons qualifying as professional investors, pursuant to article 31, paragraph 2, of CONSOB Regulation 11522/1998. Any further dissemination of this document to other persons who do not qualify as professional investors is not permitted nor is authorised by Janus Henderson Investors. Janus Henderson, Janus, Henderson, Perkins, Intech, VelocityShares, Knowledge Shared, Knowledge. Shared and Knowledge Labs are trademarks of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc. For more information or to locate your country's Janus Henderson Investors representative contact information, please visit www.janushenderson.com.